CDK4 and prostate neoplasm: The clinical trial results for prostate cancer showed that only 14% of patients on the CDK4 inhibitor alvocidib met the endpoint of 6-month PFS and the response to alvocidib single-agent activity in prostate tumors was disappointing; it should only be used in combination or as an alternative therapy (Liu et al., 2004).